US Capitol Capsule: Fixing failed emerging threat R&D model: US way best?
This article was originally published in Scrip
Executive Summary
The lack of immediate vaccines and drugs to address the Ebola crisis in West Africa starkly illuminated not only the fact the world was unprepared for yet another emerging disease threat, but the failed biopharmaceutical research and development model, which relies on profit prospects rather than health needs, the authors of a paper published earlier this month in The Lancet charged.